沙格列汀对早期2型糖尿病患者胰腺功能的改善作用

作者单位:124000 辽宁 盘锦,盘锦辽油宝石花医院急诊科

 糖尿病;2型;沙格列汀;胰岛素;胰腺;内分泌

The Improvement of Pancreatic Function in Patients with Early Type 2 Diabetes Mellitus
LI Tingting

(Emergency Department, Liaoyoubaoshihua Hospital, Panjin 124000, Liaoning Province, China)

 Diabetes Mellitus; Type 2; Sagletin; Insulin; Pancreas; Endocrine

DOI: 10.3969/j.issn.1672-7185.2020.06.014

备注

 目的  探讨沙格列汀对早期2型糖尿病( T2D M)患者胰腺功能的改善作用。方法  收集2019年1—12月盘锦辽油宝石花医院收治的T2DM患者110例,随机分为对照组和观察组各55例。对照组采用胰岛素泵强化治疗,观察组在其基础上加用沙格列汀治疗,比较两组治疗后血糖、胰腺分泌和胰岛素抵抗改善情况。结果  两组经治疗后,T2时间点C肽( C P)和 β细胞功能指数、胰岛素抵抗指数组间差异均有统计学意义(P<0.05)。结论  沙格列汀能够提高早期T2DM患者第二时相胰岛素分泌能力,并且进一步缓解胰岛素抵抗状态。
 Objective  To investigate the effect of sagletin in the improvement of pancreatic function in patients with early type 2 diabetes mellitus (T2DM) by. Methods  A total of 110 T2DM patients admitted to our hospital from January to December 2019 were randomly divided into control group and observation group with 55 cases each. The control group was treated with intensive insulin pump, and the observation group was treated with saggliptin on the basis of it. The improvement of blood glucose, pancreatic secretion and insulin resistance were compared between the two groups after treatment. Results  After treatment, there were significant differences in CP level, beta cell function index and insulin resistant indices at T2 time point between the two groups (P<0.05). Conclusion  Sagletin can improve the second phase insulin secretion in early T2DM patients, and further alleviate the state of insulin resistance.